Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study
Por:
Provencio, M, Rodriguez-Abreu, D, Ortega, AL, Serrano, G, Aguado, C, Franco, F, Gutierrez, V, Vivanco, GL, Guirado, M, Benitez, G, Estival, A, Calvo, V, Jimenez, B, Arasanz, H, Coves, J, Majem, M, Massuti, B, Vazquez, S, Juan-Vidal, O, Collazo-Lorduy, A, Gozalvez, CL, Del Barco, E, Rosero, A, Bosch-Barrerra, J, Moreno, MA, Mielgo-Rubio, X, Villa, JC, Lopez-Martin, A, Cordoba, JF, Aparisi, FD, Zafra, M, Mosquera, J, Altozano, JP, Nadal, E, Catot, S, Balsalobre, J, De Portugal, T, Martin, P, De Juan, SC, Cobo, M
Publicada:
1 ene 2022
Ahead of Print:
1 oct 2021
Resumen:
Background: At present, we did not find any articles that studied seroprevalence and its persistence several months later in lung cancer patients in the setting of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection. Most patients with coronavirus disease 2019 (COVID-19) go on to develop antibodies (Abs) against viral proteins. However, it is not known how long these Abs last nor whether cancer treatments could affect the duration of immune response. Methods: This prospective, longitudinal, multicenter serological study in the setting of SARS-CoV-2 infection was carried out in 50 Spanish hospitals. Eligibility criterion was the diagnosis of any lung cancer. The determination of anti-SARS-CoV-2 IgG Abs was performed by qualitative immuno-enzymatic assay using ELISA kit from NovaLisa whose Abs target the recombinant antigen N of the nucleocapsid of SARSCoV-2. The first Ab determination was performed between April 21 and June 3, 2020. The second Ab determination was performed in all previously seropositive patients, between September 10 and November 20, 2020. Study objectives were to prospectively determine seroprevalence in unselected lung cancer patients during the first wave of the pandemic; the persistence of immunity; protection or lack thereof against reinfection; and the influence of treatments on maintenance or loss of immunity. Results: Of 1,500 patients, 128 were seropositive, overall prevalence of 8.5% seropositivity [95% confidence interval (CI): 7.2-10.1%]. Seventy-five percent were in active cancer treatment. Forty-seven point seven percent of IgG positive participants had experienced a symptomatic illness suspected of being infected with SARS-CoV-2 (95% CI: 38.8-56.6%). A second determination was performed on average 4.5 months later [interquartile range (IQR), 4.0-5.0 months] and obtained for 104 of the initially seropositive patients (81%), it could not be obtained in 24 patients, the majority due to death caused by disease progression (73%). In the second determination, IgG was not detected in 30.8% of patients. The severity of the infection, the need for hospitalization (P=0.032) and the presence of symptoms at diagnosis (P=0.02) were associated with persistence of immunity in the second determination. No variables or treatments received were associated with Abs loss. Conclusions: Immunity against SARS-CoV-2 does not appear to be compromised by treatment and persists beyond 4 months. Neither do mortality rates appear to be particularly high in this unselected population. Trial Registration: ClinicalTrials.gov identifier: NCT04407143.
Filiaciones:
Provencio, M:
Hosp Univ Puerta de Hierro Majadahonda, Med Oncol Dept, Manuel de Falla 1, Madrid 28222, Spain
Rodriguez-Abreu, D:
Hosp Univ Insular Gran Canaria, Med Oncol Dept, Las Palmas Gran Canaria, Spain
Ortega, AL:
Hosp Univ Jaen, Med Oncol Dept, Jaen, Spain
Serrano, G:
Hosp Univ Infanta Leonor, Med Oncol Dept, Madrid, Spain
Aguado, C:
Hosp Clin San Carlos, Med Oncol Dept, Madrid, Spain
Franco, F:
Hosp Univ Puerta de Hierro Majadahonda, Med Oncol Dept, Manuel de Falla 1, Madrid 28222, Spain
Gutierrez, V:
Hosp Univ Reg Malaga, Med Oncol Dept, Malaga, Spain
Vivanco, GL:
Hosp Univ Cruces, Med Oncol Dept, Baracaldo, Spain
Guirado, M:
Hosp Gen Univ Riche, Med Oncol Dept, Alicante, Spain
Benitez, G:
Hosp Univ Insular Gran Canaria, Med Oncol Dept, Las Palmas Gran Canaria, Spain
Estival, A:
Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, IGTP, B ARGO, Badalona, Spain
Calvo, V:
Hosp Univ Puerta de Hierro Majadahonda, Med Oncol Dept, Manuel de Falla 1, Madrid 28222, Spain
Jimenez, B:
Hosp Univ HM Sanchinarro, Med Oncol Dept, Madrid, Spain
Arasanz, H:
Complejo Hosp Navarra Navarrabiomeed, Med Oncol Dept, Pamplona, Spain
Coves, J:
Hosp Univ Son LLatzex, Med Oncol Dept, Palma De Mallorca, Spain
Majem, M:
Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain
Massuti, B:
Hosp Gen Univ Alicante, Med Oncol Dept, Alicante, Spain
Vazquez, S:
Hosp Univ Lucus Augusti, Med Oncol Dept, Lugo, Spain
Juan-Vidal, O:
Hosp Univ & Politecn La Fe, Med Oncol Dept, Valencia, Spain
Collazo-Lorduy, A:
Hosp Univ Puerta de Hierro Majadahonda, Med Oncol Dept, Manuel de Falla 1, Madrid 28222, Spain
Gozalvez, CL:
Hosp Univ St Joan Reus, Med Oncol Dept, Reus, Spain
Del Barco, E:
Hosp Clin Univ Salamanca, Med Oncol Dept, Salamanca, Spain
Rosero, A:
Hosp Univ Infanta Cristina, Med Oncol Dept, Madrid, Spain
Bosch-Barrerra, J:
Inst Cat & Oncol, Med Oncol Dept, Girona, Spain
Moreno, MA:
Hosp Univ Puerto Real, Med Oncol Dept, Cadiz, Spain
Mielgo-Rubio, X:
Hosp Univ Fdn Alcorcon, Med Oncol Dept, Madrid, Spain
Villa, JC:
Hosp Gen Univ Ciudad Real, Med Oncol Dept, Ciudad Real, Spain
Lopez-Martin, A:
Hosp Univ Severo Ochoa, Med Oncol Dept, Madrid, Spain
Cordoba, JF:
Hosp Arnau Vilanova, Med Oncol Dept, Lleida, Spain
Aparisi, FD:
Hosp Gen Univ Valencia, Med Oncol Dept, Valencia, Spain
Zafra, M:
Hosp Gen Univ Morales Messeguer, Med Oncol Dept, Murcia, Spain
Mosquera, J:
Complejo Hosp Univ A Coruna, Med Oncol Dept, La Coruna, Spain
Altozano, JP:
Hosp Virgen de los Lirios, Med Oncol Dept, Alicante, Spain
Nadal, E:
Inst Catala Oncol, Med Oncol Dept, Barcelona, Spain
Catot, S:
Xarxa Assistencial Univ Manresa, Med Oncol Dept, Barcelona, Spain
Balsalobre, J:
Hosp Gen Univ Santa Lucia, Med Oncol Dept, Murcia, Spain
De Portugal, T:
Complejo Hosp Zamora, Med Oncol Dept, Zamora, Spain
Martin, P:
Hosp Clin Univ Valencia, Med Oncol Dept, Valencia, Spain
De Juan, SC:
Eurofins Megalab, Lab Cent, Madrid, Spain
Cobo, M:
Hosp Univ Reg Malaga, Med Oncol Dept, Malaga, Spain
gold
|